<DOC>
	<DOCNO>NCT01837251</DOCNO>
	<brief_summary>Evaluation best therapeutic index patient platinum-sensitive ovarian cancer treatment bevacizumab gemcitabine/carboplatin bevacizumab PLD/carboplatin .</brief_summary>
	<brief_title>Evaluation Optimal Treatment With Bevacizumab Patients With Platinum-sensitive Recurrent Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1 . Histologically confirm diagnosis epithelial ovarian carcinoma fallopian tube carcinoma primary peritoneal carcinoma 2 . First disease recurrence &gt; 6 month firstline platinumbased chemotherapy 3 . Patients measurable nonmeasurable disease ( RECIST v1.1 ) CA 125 assessable disease ( GCIG criterion ) histological proven diagnosis relapse 4 . In case cytoreductive surgery recurrence , patient must able commence cytotoxic chemotherapy within 8 week cytoreductive surgery 5 . ECOG PS 02 6 . Absolute Neutrophil Count &gt; = 1.5 x 10^9/L ; Platelets &gt; = 100 x 10^9/L ; Hemoglobin &gt; = 9.5 g/dL 7 . Patients receive anticoagulant medication International Normalized Ratio &lt; = 1.5 Activated ProThrombin Time &lt; = 1.5 x ULN 8 . Serum bilirubin &lt; = 2 x ULN ; Serum transaminases &lt; = 2.5 x ULN ( &lt; = 5 x ULN presence liver metastasis ) 9 . Serum creatinine &lt; 1.6 mg/dL creatinine clearance &gt; = 40 mL/min ; Glomerular filtration rate &gt; 40 ml/min ( estimate base CockroftGault Jelliffe formula ) ; Urine dipstick proteinuria &lt; 2+ . If urine dipstick &gt; = 2+ , 24 hour urine collection must demonstrate &lt; = 1 g protein 24 hour 10 . Normal blood pressure adequately treat controlled hypertension ( either systolic BP ≤ 140 mmHg and/or diastolic BP ≤ 90 mmHg ) 1 . Ovarian tumor low malignant potential 2 . Malignancies ovarian cancer within 5 year prior randomization 3 . Administration simultaneous chemotherapy drug , anticancer therapy antineoplastic hormonal therapy , simultaneous radiotherapy trial treatment period 4 . Any previous radiotherapy abdomen pelvis 5 . Known hypersensitivity use chemotherapeutic agent trial bevacizumab excipients , chinese hamster ovary cell product recombinant human humanise antibody 6 . Current recent chronic use aspirin &gt; 325 mg/day 7 . Surgery ( include open biopsy ) within 4 week prior anticipate first dose Bevacizumab 8 . History VEGF therapy relate abdominal fistula gastrointestinal perforation 9 . Current , clinically relevant bowel obstruction , include subocclusive disease , relate underlying disease 10 . Patients evidence abdominal free air explain paracentesis recent surgical procedure 11 . Previous CerebroVascular Accident , Transient Ischaemic Attack SubArachnoid Haemorrhage 12 . Prior history hypertensive crisis hypertensive encephalopathy 13 . Clinically significant disease , include : myocardial infarction unstable angina within ≤ 6 month randomization ; New York Heart Association ( NYHA ) &gt; = grade 2 Congestive Heart Failure ; poorly control cardiac arrhythmia despite medication ; peripheral vascular disease grade &gt; = 3 14 . LVEF define ECHO/MUGA institutional low limit normal 15 . Significant traumatic injury 4 week prior randomization 16 . Current brain metastasis spinal cord compression 17 . History evidence upon neurological examination central nervous system disease 18 . Nonhealing wound , active ulcer bone fracture 19 . History evidence thrombotic hemorrhagic disorder within 6 month prior randomization 20 . Evidence bleed diathesis significant coagulopathy ( absence therapeutic coagulation ) 21 . Fertile woman childbearing potential willing use adequate contraception ( oral contraceptive , intrauterine device barrier method contraception conjunction spermicidal jelly surgically sterile ) duration trial least 6 month afterwards 22 . Pregnant lactate woman 23 . Requirement therapeutic anticoagulation use marcumar , warfarin PTTprolonging heparin</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Ovarian Carcinoma</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>PLD</keyword>
	<keyword>pegylated liposomal doxorubicin</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>best therapeutic index</keyword>
	<keyword>progression-free survival</keyword>
</DOC>